Sydney, July 21, 2008 (ABN Newswire) - Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced today that Glypromate(R) and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising neuroscience projects available for partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
